Express Scripts adds PCSK9 inhibitors to National Preferred Formulary
ST. LOUIS. — Express Scripts this week announced that it would include two new drugs in a new class of cholesterol treatment in its National Preferred Formulary. The PCSK9 inhibitors Repatha (made by Amgen) and Praulent (made by Sanofi and Regeneron), both approved this summer for treatment of certain patients with high cholesterol, will be added to the formulary to ensure that the right patients have access to them.
“Since these new medications were approved a few months ago, our pharmacy experts have worked with medical professionals and our plan sponsors to ensure these drugs are used specifically by patients who will benefit the most,” Express Scripts SVP and chief medical officer Dr. Steve Miller, said. “We are pleased to include both drugs on our National Preferred Formulary, and to put innovative medicines within reach of patients who truly need them.”
Before the first PCSK9 inhibitor was launched, the company implemented it Cholesterol Care Value Program that works to ensure only those who really need the treatment receive it, as statins are still the best option for most high cholesterol patients, Express Scripts said. The company plans to cap plan costs for PCSK9 inhibitors in 2016 for patients in the CCV program.
“Aligned with our clients, we have achieved a more balanced marketplace, which has led to more collaborative discussions with manufacturers like Amgen, Regeneron and Sanofi, who share our interest in delivering innovative treatments to patients when clinically appropriate,” Miller said. “As a result, we are confident that we have received the best price possible for both products, without needing to exclude either.”
Accredo Specialty Pharmacy will provide patients with Praulent and Repatha, and patients will have access to pharmacists and nurses to train them how to use the injectable drugs, and will offer support and monitoring to ensure proper adherence.
“By providing specialized patient care to improve adherence, predicting which patients will best respond by using the industry's most robust set of pharmacy data, and leveraging our focused scale to drive affordability, Express Scripts uniquely creates the most value for patients and plan sponsors,” Miller said.
Americans are concerned about the security of their health data
Camber launches generic Mirapex, Plavix
PISCATAWAY, N.J. — Camber Pharmaceuticals announced Wednesday that it had launched two new generics.
One of the new launches is the company’s generic of Plavix (clopidogrel) tablets, which is indicated to prevent blood clots after heart attack or stroke, as well as in patients with heart and blood vessel disorders. The drug will be available in 20-, 90- and 500-count bottles of 75-mg tablets.
Camber has also rolled out its Mirapex (prampipexole dihydrochloride) tablets. The drug is meant to treat Parkinson’s diseases and restless legs syndrome. It will be available in 90-count bottles of 0.125-, 0.25-, 0.75, 1- and 1.5-mg tablets.